GlassScriptPhysician profile
Roosevelt Allen
NPI 1326050485
$3,809.60
in general payments reported to CMS, 2019-2025
38 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $313 · 2021: $774 · 2022: $1,059 · 2023: $709 · 2024: $328 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $500.67 | 2022 | |
| Sumitomo Pharma America, INC. | $325.20 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $278.72 | 2019-2022 | |
| Boston Scientific Corporation | $269.30 | 2019-2025 | Ams 700, Axonics, Rezum Generator |
| Myriad Genetic Laboratories, INC. | $226.34 | 2021-2024 | Prolaris |
| Astrazeneca Pharmaceuticals LP | $205.65 | 2020-2022 | |
| Endo Pharmaceuticals INC. | $183.78 | 2019-2023 | Xiaflex, Aveed |
| C. R. Bard, INC. & Subsidiaries | $168.33 | 2023 | Bard Urinary Drainage Bag |
| Pfizer INC. | $158.80 | 2019-2025 | |
| Janssen Biotech, INC. | $148.67 | 2019-2025 | Erleada, Akeega |
| Dendreon Pharmaceuticals LLC | $125.44 | 2019-2023 | Provenge |
| Myovant Sciences INC. | $123.83 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.36 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $111.92 | 2020-2023 | Keytruda, Lynparza |
| Tolmar Pharmaceuticals, INC. | $101.75 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $94.51 | 2023-2024 | |
| Amgen INC. | $66.04 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $49.76 | 2023 | Seglentis |
| Travere Therapeutics, INC. | $43.89 | 2019-2022 | |
| Antares Pharma, INC. | $43.00 | 2019-2022 | |
| Procept Biorobotics Corporation | $36.83 | 2024 | Aquabeam System |
| Neotract INC. | $36.75 | 2020 | |
| Coloplast Corp | $34.37 | 2024-2025 | |
| Abbvie INC. | $33.24 | 2024 | |
| Olympus America INC. | $32.62 | 2021-2024 | Itind System |
| Ferring Pharmaceuticals INC. | $32.44 | 2025 | Adstiladrin |
| Tempus Ai, INC | $28.95 | 2024 | |
| Baxter Healthcare | $28.56 | 2020-2022 | |
| Edap Technomed INC | $26.42 | 2025 | |
| Acerus Pharmaceuticals Corporation | $26.40 | 2020-2021 | |
| Axonics, INC. | $26.28 | 2022 | |
| Sun Pharmaceutical Industries INC. | $22.20 | 2022 | |
| Blue Earth Diagnostics | $19.79 | 2022 | |
| Lumenis, INC | $18.50 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.65 | 2022 | |
| Teleflex LLC | $15.46 | 2021 | |
| Urovant Sciences INC | $14.89 | 2021 | |
| 180 Medical, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roosevelt Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.